Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dey and State of Alabama settle Medicaid litigation
In exchange for a full release of claims, Dey has agreed to pay the state $4.75 million, of which $750,000 accounts for outside legal fees and expenses. As
In exchange for a full release of claims, Dey has agreed to pay the state $4.75 million, of which $750,000 accounts for outside legal fees and expenses. As
The company will be selling 8.7 million shares of its common stock at a price of $3 per share, which represents a 40% premium above the closing sale
The preclinical study evaluated the extent of absorption of lorazepam after nasal administration and the pharmacokinetics of the novel formulation. Amarin is working with a subsidiary of Elan
This study will evaluate the safety and pharmacokinetics of R348 in young, healthy males using a double-blind, placebo-controlled, single dose and multiple rising doses of R348. Results are
The nCounter analysis system at Washington University will be utilized first for a large-scale diabetes study to validate the expression of over 50 genes across 15 tissues in
The Phase I trial is designed to assess the safety, tolerability and pharmacokinetics, as well as preliminary antitumor activity of TRC105 in patients with advanced cancer. Charles Theuer,
The court ruled that the plaintiffs suing Pfizer failed to present reliable scientific evidence necessary to prove that Celebrex can cause heart attacks and strokes at 200mg daily
Officials at the Wisconsin Alumni Research Foundation (WARF) noted that this licensing agreement with BioTime demonstrates that commercial interest in human embryonic stem cells remains strong. With this
The Combinatorial Chemistry Center of the chemistry department of Moscow State University (MSU) has agreed to apply its expertise to provide Upstream with drug candidates for in vivo
DG051 was shown to reduce the production of leukotriene B4 (LTB4) in a dose-dependent manner. The results of the study confirm that DG051 shows reductions in LTB4 in